EAU Annual Congress 2022

EAU 2022 Prostate Cancer

• EAU 2022: Exploratory Endpoints from PROpel: A Phase III Trial of Abiraterone + Olaparib Versus Abiraterone + Placebo in 1st Line mCRPC
• EAU 2022: Discussant: Exploratory Endpoints from PROpel, a Phase III Trial of Abiraterone + Olaparib Versus Abiraterone + Placebo in First-Line mCRPC
• EAU 2022: mpMRI vs 18F-DCPyL Discussant
• EAU 2022: A Phase III Study Comparing Diagnostic Accuracy of mpMRI Prostate to 18F-DCPyL PSMA PET/CT
• EAU 2022: How Should PET-Detected Oligorecurrent Prostate Cancer Best Be Treated? Systemic Therapy

EAU 2022 Bladder Cancer

• EAU 2022: First Line Avelumab in PD-L1+ve Metastatic or Locally Advanced Urothelial Cancer (aUC) Patients Unfit for Cisplatin: The ARIES Trial
• EAU 2022: Impact of Non-Muscle Invasive Bladder Cancer Treatment History on the Efficacy of Pembrolizumab for Patients with Metastatic Urothelial Carcinoma
• EAU 2022: Biodegradable Device for Controlled Release of Cisplatin As Local Chemotherapy for Bladder Cancer
• EAU 2022: State-of-the-art Lecture Landscape of Current Trials with Intravesical Treatment in High Risk BCG naïve NMIBC

EAU 2022 Kidney Cancer

EAU 2022 Press Releases

• New Imaging Technology Less Accurate than MRI at Detecting Prostate Cancer, Trial Shows
• Only Through International Cooperation Can AI Improve Patient Lives
• Machine Learning Goes with the Flow
• Gut Microbes Differ in Men with Prostate Cancer

EAU 2022 Upper Tract Urothelial Carcinoma

• EAU 2022: Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy for UTUC Undergoing Minimally Invasive or Open Radical Nephroureterectomy: US Claims Analysis on Perioperative and Health Care Costs Outcomes
• EAU 2022: Implementing the Follow-up Schedule After Radical Nephroureterectomy for Low Risk Upper Tract Urothelial Carcinoma
• EAU 2022: The Impact of Adjuvant Chemotherapy on Overall Survival in Patients with Node-Positive Upper Tract Urothelial Carcinoma: Improving Precision in Medicine with a Risk-Stratified Approach
• EAU 2022: Elevated Hemoglobin: Creatinine Ratio Is a Novel Preoperative Marker for Worsened Survival Outcomes in Upper Tract Urothelial Carcinoma: Analysis from the ROBUUST Registry
• EAU 2022: Eleven Years of Experience with UTUC: Survival and Renal Function After Kidney Sparing Surgery Versus Radical Nephroureterectomy